Nomos and Zmed settle
'Tis the season for burying the hatchet. A settlement last month by R2 and iCAD over patent infringement was followed Sept. 19 by the announcement that Nomos and Zmed had settled their differences. The radiotherapy companies put to rest two pending
'Tis the season for burying the hatchet. A settlement last month by R2 and iCAD over patent infringement was followed Sept. 19 by the announcement that Nomos and Zmed had settled their differences. The radiotherapy companies put to rest two pending patent infringement suits relating to patient positioning and target verification products, namely Nomos BAT and BAT SXi products and Zmed's SonArray product. The agreement resolves all claims and provides cross-licensing of patent rights.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
